AAAAAA

   
Results: 1-3 |
Results: 3
COX-2 inhibitors and cardiovascular risk - The data are inconclusive, and these drugs are needed
Authors: Lipani, J
Citation: J. Lipani, COX-2 inhibitors and cardiovascular risk - The data are inconclusive, and these drugs are needed, CLEV CLIN J, 68(11), 2001, pp. 961-962
Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: Towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies
Authors: Woodworth, TG Furst, DE Strand, V Kempeni, J Fenner, H Lau, CS Miller, F Day, R Lipani, J Brooks, P
Citation: Tg. Woodworth et al., Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: Towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies, J RHEUMATOL, 28(5), 2001, pp. 1163-1169
Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL
Authors: Deeg, HJ Blazar, BR Bolwell, BJ Long, GD Schuening, F Cunningham, J Rifkin, RM Abhyankar, S Briggs, AD Burt, R Lipani, J Roskos, LK White, JM Havrilla, N Schwab, G Heslop, HE
Citation: Hj. Deeg et al., Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL, BLOOD, 98(7), 2001, pp. 2052-2058
Risultati: 1-3 |